Table 2 Patient characteristics by treatment cohort
Variables | before PSM | after PSM | ||||
|---|---|---|---|---|---|---|
Monotherapy cohort | Combined therapy cohort | P value | Monotherapy cohort | Combined therapy cohort | P value | |
n = 19 | n = 46 | n = 16 | n = 16 | |||
Age, years | 63.0(52.0–68.0) | 62.5(55.0–67.0) | 0.965 | 63.0(50.5–67.5) | 60.5(53.0-64.8) | 0.539 |
Gender | 0.085 | 0.723 | ||||
Female | 11(57.9%) | 16(34.8%) | 9(56.3%) | 8(50.0%) | ||
Male | 8(42.1%) | 30(65.2%) | 7(43.8%) | 8(50.0%) | ||
ECOG PS score | 0.562 | 1.000 | ||||
0 | 11(57.9%) | 23(50.0%) | 9(56.3%) | 9(56.3%) | ||
1 | 8(42.1%) | 23(50.0%) | 7(43.8%) | 7(43.8%) | ||
CA19-9 | 0.166 | 1.000 | ||||
Normal (≤ 37 U/ml) | 11(57.9%) | 18(39.1%) | 9(56.3%) | 9(56.3%) | ||
Abnormal (> 37 U/ml) | 8(42.1%) | 28(60.9%) | 7(43.8%) | 7(43.8%) | ||
CEA | 0.260 | 1.000 | ||||
Normal (≤ 5 ng/mL) | 12(63.2%) | 22(47.8%) | 11(68.8%) | 11(68.8%) | ||
Abnormal (> 5 ng/mL) | 7(36.8%) | 24(52.2%) | 5(31.3%) | 5(31.3%) | ||
Disease status | 0.083 | 1.000 | ||||
Locally advanced16 | 0(0.0%) | 6(13.0%) | 0(0.0%) | 0(0.0%) | ||
Metastatic | 9(47.4%) | 27(58.7%) | 8(50.0%) | 8(50.0%) | ||
Recurrent | 10(52.6%) | 13(28.3%) | 8(50.0%) | 8(50.0%) | ||
Tumor number | 0.789 | 1.000 | ||||
1 | 6(31.6%) | 13(28.3%) | 6(37.5%) | 6(37.5%) | ||
≥ 2 | 13(68.4%) | 33(71.7%) | 10(62.5%) | 10(62.5%) | ||
Site of metastases | ||||||
Liver | 14(73.7%) | 30(65.2%) | 0.507 | 12(75.0%) | 12(75.0%) | 1.000 |
Lymph node | 5(26.3%) | 23(50.0%) | 0.079 | 5(31.3%) | 7(43.8%) | 0.465 |
Peritoneum | 4(21.1%) | 6(13.0%) | 0.663 | 3(18.8%) | 1(6.3%) | 0.600 |
Lung | 3(15.8%) | 4(8.7%) | 0.408 | 1(6.3%) | 3(18.8%) | 0.600 |
Bone | 0(0.0%) | 2(4.3%) | 1.000 | 0(0.0%) | 0(0.0%) | 1.000 |
Previous therapy | ||||||
Surgery | 10(52.6%) | 13(28.3%) | 0.062 | 8(50.0%) | 8(50.0%) | 1.000 |
ablation | 1(5.3%) | 0(0.0%) | 0.292 | 0(0.0%) | 0(0.0%) | 1.000 |
TACE | 0(0.0%) | 1(2.2%) | 1.000 | 0(0.0%) | 0(0.0%) | 1.000 |